IA
FATE icon

IFP Advisors’s Fate Therapeutics FATE Stock Holding History

IFP Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-800
Closed -$10K – 2680
2018
Q4 		$10K Sell
800
-3,200
-80% -$44.6K ﹤0.01% 2500
2018
Q3 		$65K Sell
4,000
-12,000
-75% -$142K ﹤0.01% 1743
2018
Q2 		$181K Buy
+16,000
New +$176K 0.01% 1114

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

IFP Advisors's FATE Position: Q2 2026 in Review

IFP Advisors increased its Fate Therapeutics (FATE) stake by 12% in Q2 2026, buying an estimated $207 and bringing the position to 1,020 shares worth $2.75K. The position accounts for ﹤0.01% of the portfolio, ranked #4086.

IFP Advisors first reported a position in FATE in Q4 2015 and has held it in 30 quarters since. The position peaked at $342K in Q3 2018. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • IFP Advisors held 1,020 shares of Fate Therapeutics worth $2.75K as of Q2 2026.
  • IFP Advisors bought 112 Fate Therapeutics shares in Q2 2026, an estimated $207.
  • Fate Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4086 holding.
  • IFP Advisors first reported a position in Fate Therapeutics in Q4 2015 and has held it in 30 quarters since.
  • IFP Advisors's Fate Therapeutics position peaked at $342K in Q3 2018.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.